Midwest Trust Co Reduces Stake in Merck & Co., Inc. $MRK

Midwest Trust Co reduced its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 2.5% in the first quarter, Holdings Channel reports. The fund owned 747,618 shares of the company’s stock after selling 19,353 shares during the quarter. Merck & Co., Inc. accounts for about 1.1% of Midwest Trust Co’s portfolio, making the stock its 18th largest position. Midwest Trust Co’s holdings in Merck & Co., Inc. were worth $89,931,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Kingdom Financial Group LLC. purchased a new position in Merck & Co., Inc. in the fourth quarter valued at approximately $25,000. Abound Financial LLC purchased a new stake in Merck & Co., Inc. in the fourth quarter worth $26,000. Prosperity Bancshares Inc bought a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at $26,000. United Financial Planning Group LLC bought a new stake in shares of Merck & Co., Inc. in the third quarter valued at $31,000. Finally, High Note Wealth LLC raised its stake in shares of Merck & Co., Inc. by 58.9% in the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after buying an additional 109 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Price Performance

NYSE MRK traded down $1.35 on Friday, hitting $123.72. The stock had a trading volume of 8,388,403 shares, compared to its average volume of 10,797,806. Merck & Co., Inc. has a 52-week low of $76.66 and a 52-week high of $130.29. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The company has a market capitalization of $305.56 billion, a price-to-earnings ratio of 34.85, a price-to-earnings-growth ratio of 2.65 and a beta of 0.19. The firm has a 50-day moving average of $118.83 and a 200-day moving average of $116.28.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. The company had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm’s revenue was up 4.9% compared to the same quarter last year. During the same quarter last year, the business posted $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Equities analysts expect that Merck & Co., Inc. will post 5.17 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th were issued a $0.85 dividend. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.7%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 95.77%.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA approved KEYTRUDA and KEYTRUDA QLEX, each combined with Padcev, for use before and after surgery in adults with muscle-invasive bladder cancer. This expands Merck’s flagship oncology franchise and could add to future revenue. Article Title
• Positive Sentiment: Analyst sentiment remains constructive, with Morgan Stanley slightly raising its price target and RBC Capital reiterating a Buy rating. That suggests Wall Street still sees upside despite the stock’s recent run. Article Title
• Positive Sentiment: Merck continues to attract investor attention thanks to strong year-to-date performance, a solid dividend yield, and a long record of dividend growth, which may support demand for the shares. Article Title
• Neutral Sentiment: Recent coverage also notes Merck is one of the more widely watched healthcare names on Zacks, but these mentions do not appear to add any new fundamental catalyst on their own. Article Title
• Negative Sentiment: Despite the upbeat news flow, the shares also face ongoing valuation and post-KEYTRUDA exclusivity concerns, which may limit upside if investors focus on Merck’s long-term patent risk. Article Title

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on MRK. CICC Research assumed coverage on Merck & Co., Inc. in a research note on Wednesday, June 24th. They set an “outperform” rating and a $138.00 price target for the company. Morgan Stanley boosted their price objective on Merck & Co., Inc. from $112.00 to $113.00 and gave the company an “equal weight” rating in a research note on Thursday. Wells Fargo & Company upped their price objective on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday. Citigroup started coverage on shares of Merck & Co., Inc. in a research note on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 target price for the company. Finally, Wall Street Zen raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Sunday. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $132.72.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.